GUBRAC Stock Overview

A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. More details

GUBRAC fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 72.6% below our estimate of its fair value

Earnings are forecast to grow 7.94% per year

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Gubra A/S Competitors

Oxford Nanopore Technologies

LSE:ONT

UK£1.2b

MaxCyte

AIM:MXCT

UK£219.0m

hVIVO

AIM:HVO

UK£125.2m

Diaceutics

AIM:DXRX

UK£101.8m

Price History & Performance

Summary of share price highs, lows and changes for Gubra
Historical stock prices
Current Share Price	DKK 673.00
52 Week High	DKK 728.00
52 Week Low	DKK 391.00
Beta	0.51
1 Month Change	0%
3 Month Change	5.82%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	329.35%

Recent updates

Shareholder Returns

	GUBRAC	GB Life Sciences	GB Market
7D	0%	3.7%	2.1%
1Y	n/a	-9.5%	2.2%

Return vs Industry: Insufficient data to determine how GUBRAC performed against the UK Life Sciences industry.

Return vs Market: Insufficient data to determine how GUBRAC performed against the UK Market.

Price Volatility

Is GUBRAC's price volatile compared to industry and market?
GUBRAC volatility
GUBRAC Average Weekly Movement	n/a
Life Sciences Industry Average Movement	7.5%
Market Average Movement	5.7%
10% most volatile stocks in GB Market	10.8%
10% least volatile stocks in GB Market	3.1%

Stable Share Price: GUBRAC's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine GUBRAC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	260	Henrik Blou	www.gubra.dk

Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, pharmacokinetics, and 2D and 3D histology with artificial intelligence pathology.

Gubra A/S Fundamentals Summary

How do Gubra's earnings and revenue compare to its market cap?
GUBRAC fundamental statistics
Market cap	DKK 6.38b
Earnings (TTM)	-DKK 36.50m
Revenue (TTM)	DKK 265.74m

24.0x

P/S Ratio

-174.7x

P/E Ratio

Is GUBRAC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GUBRAC income statement (TTM)
Revenue	DKK 265.74m
Cost of Revenue	DKK 101.24m
Gross Profit	DKK 164.50m
Other Expenses	DKK 201.00m
Earnings	-DKK 36.50m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Aug 21, 2025

Earnings per share (EPS)	-2.24
Gross Margin	61.90%
Net Profit Margin	-13.73%
Debt/Equity Ratio	0%

How did GUBRAC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/06 01:05
End of Day Share Price	2025/02/12 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gubra A/S is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Rune Dahl	DNB Markets